Study Results Show Shorter Radiation for Breast Cancer is ‘Worthy of Further Study’

Video

An expert from the Mayo Clinic notes that there’s also a great amount of interest in further optimizing the dose of radiation after mastectomy, especially in patients with breast cancer immediately following reconstruction.

Optimizing the dose and fractionation regimen are some of the next steps in further developing postmastectomy radiation therapy in breast cancer, according to an expert from Mayo Clinic.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with Robert Mutter, MD, a member of Mayo Clinic Cancer Center in Rochester, Minnesota, about future research for postmastectomy radiotherapy in the treatment of patients with breast cancer.

According to Mutter, future research in the field includes the RT CHARM trial (NCT03414970), which is evaluating photon postmastectomy radiation among patients who have undergone an immediate breast reconstruction.


Transcript:

There is an ongoing photon postmastectomy radiation trial for patients who have an immediate [breast] reconstruction. This is called the RT CHARM trial, and it’s actually completed accrual, so we’re eagerly awaiting those results, which should be sometime in late 2023, or 2024.

Our results suggest that hypofractionated proton postmastectomy radiation therapy is also worthy of further study. Certainly, there’s also a great interest in further optimizing the dose and fractionation regimen for postmastectomy radiation therapy, in particular, for patients with immediate reconstruction. These are patients who still have relatively high rates of complications whether they’re treated with photons, or, as we’ve seen in our study, with proton therapy because we observed similar rates of complications as what has been reported in the literature with photons.

Reference

Mutter R, Giri S, Fruth B, et al. Phase II randomized trial of conventional versus hypofractionated post-mastectomy proton radiotherapy. Presented at the 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX. Abstract GS4-05.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content